Diabetes reversal company Virta Health revealed on Wednesday that it has completed USD65m in Series D funding led by Sequoia Capital Global Equities, with participation from Caffeinated Capital.

The funding will be used to accelerate Virta's provider-led virtual care delivery platform, Continuous Remote Care, which is the backbone for its transformative reversal therapies. It will expand research and development of evidence-based, non-pharmaceutical therapies for other complex and costly metabolic conditions. It will restore metabolic health and eliminate the need for costly medications like insulin.

This round brings total the funding to more than USD230m and values Virta Health at over USD1.1bn.

SCGE invests primarily in public companies and late-stage private companies, focusing on identifying disruptive technology themes and investing behind long-term winners in large markets undergoing secular disruption.